xtl logo 88.
(photo credit: )
Rehovot-based XTL Biopharmaceuticals named Ron Bentsur as chief executive, ending an 11-month period without a CEO.
In February, rebel investors persuaded shareholders to oust interim chairman and chief executive Elkan Gamzu and two other directors. XTL appointed Michael Weiss as interim chairman in March and then non-executive chairman in August, but failed to appoint a CEO until now.
XTL said on Tuesday that Bentsur comes from US company Keryx Biopharmaceuticals, where he is vice president for finance and investor relations, a job he will continue to carry out for a transitional period.